Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167024 | 0.85 | TRPV1 (0.54) | TRPV1EGFR | |
| SCHEMBL4150099 | 0.82 | TRPV1 (0.56) | TRPV1CNR1 | |
| SCHEMBL4162780 | 0.82 | GRM4 (0.43) | TRPV1EGFRTHRBAURKARPS6KB1 | |
| SCHEMBL4155409 | 0.80 | KDM4E (0.48) | TRPV1EGFRTHRBLMNATP53 | |
| SCHEMBL4164555 | 0.75 | TRPV1 (0.55) | TRPV1AURKA | |
| SCHEMBL13801581 | 0.75 | TRPV1 (0.59) | TRPV1EGFR | |
| SCHEMBL4148677 | 0.75 | TRPV1 (0.54) | TRPV1EGFR | |
| SCHEMBL4016814 | 0.73 | TRPV1 (0.85) | TRPV1 | |
| SCHEMBL4162708 | 0.70 | TRPV1 (0.44) | TRPV1EGFRLMNA | |
| SCHEMBL4158353 | 0.69 | TRPV1 (0.44) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | claimed |
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156598-A1 | Imidazolopyrimidine modulators of TRPV1 | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885EGFR 2826/4885THRB 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.